| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MPD; FP17780 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human MVD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于USP22抗体的3篇代表性文献摘要简述：
1. **"USP22 regulates the Warburg effect and tumorigenesis via deubiquitinating PKM2"**
*作者：Li et al. (2023)*
摘要：研究发现USP22通过去泛素化丙酮酸激酶M2(PKM2)调控肿瘤细胞的有氧糖酵解(Warburg效应)，促进结直肠癌进展。研究中USP22抗体被用于检测其蛋白表达水平及亚细胞定位。
2. **"USP22 promotes tumor progression via stabilization of EZH2 in hepatocellular carcinoma"**
*作者：Wang et al. (2021)*
摘要：该文献揭示USP22通过稳定组蛋白甲基转移酶EZH2增强肝癌细胞侵袭性，USP22抗体在机制研究中用于免疫共沉淀(Co-IP)验证USP22与EZH2的相互作用。
3. **"A stem cell-like signature of USP22 expression predicts poor prognosis in gastric cancer"**
*作者：Zhang et al. (2019)*
摘要：通过免疫组化(IHC)结合USP22抗体分析胃癌组织样本，发现USP22高表达与患者生存期缩短显著相关，提示其作为预后标志物和治疗靶点的潜力。
如需具体实验条件或文献链接，可进一步补充研究方向(如癌症类型或实验方法)。
The ubiquitin-specific protease 22 (USP22) is a deubiquitinating enzyme (DUB) belonging to the ubiquitin-specific protease family, which plays a critical role in regulating protein stability and function by removing ubiquitin chains from target proteins. USP22 is a key component of the human telomerase reverse transcriptase (hTERT)- and Polycomb-repressive deubiquitination (PR-DUB) complex, where it modulates transcriptional regulation, epigenetic modifications, and cellular processes such as cell cycle progression, apoptosis, and stem cell renewal. Notably, USP22 is implicated in cancer biology due to its role in stabilizing oncoproteins (e.g., c-Myc, HIF-1α) and promoting tumor growth, metastasis, and therapy resistance. Its overexpression is associated with poor prognosis in various cancers, making it a potential therapeutic target.
USP22 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Validating USP22 antibodies requires specificity testing, often through knockout cell lines or siRNA-mediated knockdown, to ensure minimal cross-reactivity with other USP family members. Researchers also rely on these antibodies to explore USP22's regulatory mechanisms in diseases, including cancer, neurodegenerative disorders, and metabolic syndromes. The development of high-affinity, well-characterized USP22 antibodies continues to advance research into its biological roles and therapeutic potential.
×
